Discretionary transaction by Abramowitz Israel Maxx of tradable shares of Pasithea Therapeutics subject to Rule 16b-3
KTTA Stock | USD 1.11 0.07 6.73% |
About 56% of all Pasithea Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Pasithea Therapeutics Corp suggests that some traders are interested. The current market sentiment, together with Pasithea Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Pasithea Therapeutics stock news signals to limit their universe of possible portfolio assets.
Pasithea |
Filed transaction by Pasithea Therapeutics Corp Executive. Discretionary transaction in accordance with Rule 16b-3
Read at macroaxis.com
Pasithea Therapeutics Fundamental Analysis
We analyze Pasithea Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pasithea Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pasithea Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Pasithea Therapeutics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Pasithea Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pasithea Therapeutics stock to make a market-neutral strategy. Peer analysis of Pasithea Therapeutics could also be used in its relative valuation, which is a method of valuing Pasithea Therapeutics by comparing valuation metrics with similar companies.
Peers
Pasithea Therapeutics Related Equities
NTRBW | Nutriband Warrant | 7.35 | ||||
VRAX | Virax Biolabs | 6.20 | ||||
MNOV | MediciNova | 5.44 | ||||
REVB | Revelation Biosciences | 3.98 | ||||
QNRX | Quoin Pharmaceuticals | 3.45 | ||||
KRON | Kronos Bio | 2.17 | ||||
KZR | Kezar Life | 0.69 | ||||
KPRX | Kiora Pharmaceuticals | 0.31 | ||||
RNXT | RenovoRx | 2.94 | ||||
FBRX | Forte Biosciences | 3.33 | ||||
INDP | Indaptus Therapeutics | 3.57 | ||||
ABVC | ABVC Biopharma | 5.80 |
Complementary Tools for Pasithea Stock analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Valuation Check real value of public entities based on technical and fundamental data |